Aripiprazole long-acting injectable (ABILIFY MAINTENA) for treatment of schizophrenia

ABSTRACT Introduction: Patients with schizophrenia often relapse as a result of medication nonadherence. Methods: Long-acting injectable antipsychotics have been developed to improve medication adherence rates in this patient population. Results: Aripiprazole long-acting injection (LAI), branded Abilify Maintena®, received Food and Drug Administration approval for the treatment of schizophrenia in February of 2013. Aripiprazole LAI is the fourth intramuscular second-generation antipsychotic indicated for the treatment of schizophrenia. Discussion: This manuscript reviews important clinical information regarding its use as well as efficacy and tolerability data.